{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:32:55Z","timestamp":1788172375498,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["215S752"],"award-info":[{"award-number":["215S752"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inonu University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study investigates the cardiovascular effects of the synthetic cannabinoid naphthalene-1-yl-(1-pentylindole-3-yl)methanone (JWH-018) in rats. The research aims to evaluate the pharmacologic, cardiologic, biochemical, and histopathological effects of acute and subacute administration at low and high doses. The primary research question is how JWH-018 impacts heart function, blood pressure, ECG patterns, and cardiac tissue integrity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Wistar albino rats were divided into five groups: control, acute low-dose (ALD, 0.5\u00a0mg\/kg), acute high-dose (AHD, 5\u00a0mg\/kg), subacute low-dose (SALD, 0.5\u00a0mg\/kg for 14\u00a0days), and subacute high-dose (SAHD, 5\u00a0mg\/kg for 14\u00a0days). Cardiovascular effects were assessed using echocardiography, hemodynamic and ECG analysis, histopathology, biochemical markers, and LC\u2013MS\/MS quantification of JWH-018 and its metabolites in heart tissue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Acute high-dose JWH-018 caused bradycardia and hypotension, while subacute high-dose increased heart rate but continued to lower blood pressure. JWH-018 induced cardiac arrhythmias, conduction blocks, and ischemic ECG changes, with prolonged QT intervals in subacute high-dose rats. Histopathological findings revealed myocardial infarction-like features, including contraction bands and ischemic damage, particularly in subacute groups. Elevated pro-BNP and triglycerides indicated cardiac stress and metabolic effects. JWH-018 and its metabolites were detected in heart tissue, primarily in high-dose groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>JWH-018 has significant cardiovascular risks, causing heart rate dysregulation, hypotension, arrhythmias, and ischemic damage. These effects depend on dose and duration. The study highlights the potential dangers of synthetic cannabinoids, emphasizing that they should not be considered safe alternatives to natural cannabis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11419-025-00720-9","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:18:51Z","timestamp":1744816731000},"page":"266-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute and subacute cardiovascular effects of synthetic cannabinoid JWH-018 in rat"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-7849","authenticated-orcid":false,"given":"Onural","family":"Ozhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necip","family":"Ermis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Celbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Samdanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semih","family":"Petekkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mucahit","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozcan","family":"Soylu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Koparir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Acet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Parlakpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"720_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","volume":"120","author":"R Vandrey","year":"2012","unstructured":"Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend 120:238\u2013241. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.07.011","journal-title":"Drug Alcohol Depend"},{"key":"720_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1096\/fasebj.12.11.1035","volume":"12","author":"K Varga","year":"1998","unstructured":"Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035\u20131044. https:\/\/doi.org\/10.1096\/fasebj.12.11.1035","journal-title":"FASEB J"},{"key":"720_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, B\u00e1tkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389\u2013462. https:\/\/doi.org\/10.1124\/pr.58.3.2","journal-title":"Pharmacol Rev"},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/157016107781024109","volume":"5","author":"JC Ashton","year":"2007","unstructured":"Ashton JC, Smith PF (2007) Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol 5:175\u2013185. https:\/\/doi.org\/10.2174\/157016107781024109","journal-title":"Curr Vasc Pharmacol"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/HYPERTENSIONAHA.105.063651","volume":"52","author":"P Pacher","year":"2008","unstructured":"Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, B\u00e1tkai S, Kunos G (2008) Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 52:601\u2013607. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.105.063651","journal-title":"Hypertension"},{"key":"720_CR6","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.21037\/jtd.2017.06.104","volume":"9","author":"H Goyal","year":"2017","unstructured":"Goyal H, Awad HH, Ghali JK (2017) Role of cannabis in cardiovascular disorders. J Thorac Dis 9:2079\u20132092. https:\/\/doi.org\/10.21037\/jtd.2017.06.104","journal-title":"J Thorac Dis"},{"key":"720_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00281-009-0145-8","volume":"31","author":"P Pacher","year":"2009","unstructured":"Pacher P, Steffens S (2009) The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 31:63\u201377. https:\/\/doi.org\/10.1007\/s00281-009-0145-8","journal-title":"Semin Immunopathol"},{"key":"720_CR8","unstructured":"Nelson MA (2021) Mechanisms of synthetic cannabinoids on cardiovascular health. 2021"},{"key":"720_CR9","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1542\/peds.2010-3823","volume":"128","author":"A Mir","year":"2011","unstructured":"Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:1622\u20131627. https:\/\/doi.org\/10.1542\/peds.2010-3823","journal-title":"Pediatrics"},{"key":"720_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.ajem.2011.05.013","volume":"30","author":"AC Young","year":"2012","unstructured":"Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, Kleinschmidt K (2012) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 30:1320. https:\/\/doi.org\/10.1016\/j.ajem.2011.05.013","journal-title":"Am J Emerg Med"},{"key":"720_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/cpt.114","volume":"97","author":"MK Su","year":"2015","unstructured":"Su MK, Seely KA, Moran JH, Hoffman RS (2015) Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther 97:562\u2013564. https:\/\/doi.org\/10.1002\/cpt.114","journal-title":"Clin Pharmacol Ther"},{"key":"720_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","volume":"18","author":"ZD Cooper","year":"2016","unstructured":"Cooper ZD (2016) Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 18:52. https:\/\/doi.org\/10.1007\/s11920-016-0694-1","journal-title":"Curr Psychiatry Rep"},{"key":"720_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U (2018) Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 19:833. https:\/\/doi.org\/10.3390\/ijms19030833","journal-title":"Int J Mol Sci"},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00005344-200304000-00020","volume":"41","author":"A Bonz","year":"2003","unstructured":"Bonz A, Laser M, K\u00fcllmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA (2003) Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41:657\u2013664. https:\/\/doi.org\/10.1097\/00005344-200304000-00020","journal-title":"J Cardiovasc Pharmacol"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2337\/db11-0477","volume":"61","author":"M Rajesh","year":"2012","unstructured":"Rajesh M, B\u00e1tkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horv\u00e1th B, Holovac E, Cinar R, Liaudet L, Mackie K, Hask\u00f3 G, Pacher P (2012) Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61:716\u2013727. https:\/\/doi.org\/10.2337\/db11-0477","journal-title":"Diabetes"},{"key":"720_CR16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1006\/bbrc.1998.8187","volume":"243","author":"T Sugiura","year":"1998","unstructured":"Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K (1998) Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 243:838\u2013843. https:\/\/doi.org\/10.1006\/bbrc.1998.8187","journal-title":"Biochem Biophys Res Commun"},{"issue":"1995","key":"720_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Gali\u00e8gue","year":"1995","unstructured":"Gali\u00e8gue S, Mary S, Marchand J, Dussossoy D, Carri\u00e8re D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232(1995):54\u201361. https:\/\/doi.org\/10.1111\/j.1432-1033.1995.tb20780.x","journal-title":"Eur J Biochem"},{"key":"720_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00210-003-0755-y","volume":"367","author":"N Niederhoffer","year":"2003","unstructured":"Niederhoffer N, Schmid K, Szabo B (2003) The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 367:434\u2013443. https:\/\/doi.org\/10.1007\/s00210-003-0755-y","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"720_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","volume":"69","author":"M Czeisler","year":"2020","unstructured":"Czeisler M, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, Weaver MD, Robbins R, Facer-Childs ER, Barger LK, Czeisler CA, Howard ME, Rajaratnam SMW (2020) Mental health, substance use, and suicidal ideation during the COVID-19 pandemic-United States, June 24\u201330, 2020. MMWR Morb Mortal Wkly Rep 69:1049","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"720_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s12272-021-01326-6","volume":"44","author":"EY Chung","year":"2021","unstructured":"Chung EY, Cha HJ, Min HK, Yun J (2021) Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch Pharm Res 44:402\u2013413. https:\/\/doi.org\/10.1007\/s12272-021-01326-6","journal-title":"Arch Pharm Res"},{"key":"720_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/7854_2016_60","volume":"32","author":"S Tai","year":"2017","unstructured":"Tai S, Fantegrossi WE (2017) Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. Curr Top Behav Neurosci 32:249\u2013262. https:\/\/doi.org\/10.1007\/7854_2016_60","journal-title":"Curr Top Behav Neurosci"},{"key":"720_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11419-018-0415-z","volume":"36","author":"CT Schoeder","year":"2018","unstructured":"Schoeder CT, Hess C, Madea B, Meiler J, M\u00fcller CE (2018) Pharmacological evaluation of new constituents of \u201cSpice\u201d: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicol 36:385\u2013403. https:\/\/doi.org\/10.1007\/s11419-018-0415-z","journal-title":"Forensic Toxicol"},{"issue":"2018","key":"720_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/JMAU.JMAU_42_18","volume":"6","author":"BG Eid","year":"2018","unstructured":"Eid BG (2018) Cannabinoids for treating cardiovascular disorders: putting together a complex puzzle. J Microsc Ultrastruct 6(2018):171\u2013176. https:\/\/doi.org\/10.4103\/JMAU.JMAU_42_18","journal-title":"J Microsc Ultrastruct"},{"key":"720_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/acschemneuro.5b00107","volume":"6","author":"SD Banister","year":"2015","unstructured":"Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2015) Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 6:1445\u20131458. https:\/\/doi.org\/10.1021\/acschemneuro.5b00107","journal-title":"ACS Chem Neurosci"},{"key":"720_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) NC3Rs Reporting Guidelines Working Group. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160:1577\u20131579. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00872.x","journal-title":"Br J Pharmacol"},{"key":"720_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cvr\/22.7.447","volume":"22","author":"MJA Walker","year":"1988","unstructured":"Walker MJA, Curtis M, Hearse DJ, Campbell RWF, Riva E, Janse M, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW (1988) The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 22:447\u2013455. https:\/\/doi.org\/10.1093\/cvr\/22.7.447","journal-title":"Cardiovasc Res"},{"key":"720_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.arcmed.2013.09.013","volume":"44","author":"R Bentli","year":"2013","unstructured":"Bentli R, Parlakpinar H, Polat A, Samdanci E, Sarihan ME, Sagir M (2013) Molsidomine prevents cisplatin-induced hepatotoxicity. Arch Med Res 44:521\u2013528. https:\/\/doi.org\/10.1016\/j.arcmed.2013.09.013","journal-title":"Arch Med Res"},{"key":"720_CR28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/bmc.2710","volume":"26","author":"JL Poklis","year":"2012","unstructured":"Poklis JL, Amira D, Wise LE, Wiebelhaus JM, Haggerty BJ, Lichtman AH, Poklis A (2012) Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to \u201cbuzz\u201d smoke by HPLC\/MS\/MS. Biomed Chromatogr 26:1393\u20131398. https:\/\/doi.org\/10.1002\/bmc.2710","journal-title":"Biomed Chromatogr"},{"key":"720_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.forsciint.2012.02.003","volume":"220","author":"JL Poklis","year":"2012","unstructured":"Poklis JL, Amira D, Wise LE, Wiebelhaus JM, Haggerty BJ, Poklis A (2012) Detection and disposition of JWH-018 and JWH-073 in mice after exposure to \u201cMagic Gold\u201d smoke. Forensic Sci Int 220:91\u201396. https:\/\/doi.org\/10.1016\/j.forsciint.2012.02.003","journal-title":"Forensic Sci Int"},{"key":"720_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-3-319-20825-1_14","volume":"231","author":"SE O'Sullivan","year":"2015","unstructured":"O\u2019Sullivan SE (2015) Endocannabinoids and the cardiovascular system in health and disease. Handb Exp Pharmacol 231:393\u2013422. https:\/\/doi.org\/10.1007\/978-3-319-20825-1_14","journal-title":"Handb Exp Pharmacol"},{"key":"720_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12012-019-09522-z","volume":"19","author":"HM Ozturk","year":"2019","unstructured":"Ozturk HM, Yetkin E, Ozturk S (2019) Synthetic cannabinoids and cardiac arrhythmia risk: review of the literature. Cardiovasc Toxicol 19:191\u2013197. https:\/\/doi.org\/10.1007\/s12012-019-09522-z","journal-title":"Cardiovasc Toxicol"},{"key":"720_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jemermed.2015.10.009","volume":"50","author":"J Von Der Haar","year":"2016","unstructured":"Von Der Haar J, Talebi S, Ghobadi F, Singh S, Chirurgi R, Rajeswari P, Kalantari H, Hassen GW (2016) Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med 50:258\u2013262. https:\/\/doi.org\/10.1016\/j.jemermed.2015.10.009","journal-title":"J Emerg Med"},{"key":"720_CR33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.5455\/medscience.2016.05.8452","volume":"5","author":"H Parlakpinar","year":"2016","unstructured":"Parlakpinar H, Celbis O, Ozhan O, Petekkaya S, Samdanci E, Ermis N, Koparir P, Soylu O, Acet A (2016) Cardiovascular effects of JWH-018 from synthetic cannabinoids. Med Sci 5:1049","journal-title":"Med Sci"},{"key":"720_CR34","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0022-3565(24)36714-X","volume":"281","author":"KD Lake","year":"1997","unstructured":"Lake KD, Compton DR, Varga K, Martin BR, Kunos G (1997) Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281:1030\u20131037","journal-title":"J Pharmacol Exp Ther"},{"key":"720_CR35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.bjp.0704565","volume":"135","author":"WR Ford","year":"2002","unstructured":"Ford WR, Honan SA, White R, Hiley CR (2002) Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 135:1191\u20131198. https:\/\/doi.org\/10.1038\/sj.bjp.0704565","journal-title":"Br J Pharmacol"},{"key":"720_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1161\/01.hyp.28.4.682","volume":"28","author":"K Varga","year":"1996","unstructured":"Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28:682\u2013686. https:\/\/doi.org\/10.1161\/01.hyp.28.4.682","journal-title":"Hypertension"},{"key":"720_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.283.5400.401","volume":"283","author":"C Ledent","year":"1999","unstructured":"Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, B\u00f6hme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401\u2013404. https:\/\/doi.org\/10.1126\/science.283.5400.401","journal-title":"Science"},{"issue":"2004","key":"720_CR38","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/01.CIR.0000143230.23252.D2","volume":"110","author":"S B\u00e1tkai","year":"2004","unstructured":"B\u00e1tkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offert\u00e1ler L, Mackie K, Rudd MA, Bukoski RD, Kunos G (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110(2004):1996\u20132002. https:\/\/doi.org\/10.1161\/01.CIR.0000143230.23252.D2","journal-title":"Circulation"},{"key":"720_CR39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/j.1476-5381.1996.tb15639.x","volume":"118","author":"EJ Ishac","year":"1996","unstructured":"Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023\u20132028. https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb15639.x","journal-title":"Br J Pharmacol"},{"key":"720_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/pl00005041","volume":"356","author":"B Malinowska","year":"1997","unstructured":"Malinowska B, Godlewski G, Bucher B, Schlicker E (1997) Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol 356:197\u2013202. https:\/\/doi.org\/10.1007\/pl00005041","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"720_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0014-2999(01)01112-8","volume":"423","author":"JA Wagner","year":"2001","unstructured":"Wagner JA, J\u00e1rai Z, B\u00e1tkai S, Kunos G (2001) Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423:203\u2013210. https:\/\/doi.org\/10.1016\/s0014-2999(01)01112-8","journal-title":"Eur J Pharmacol"},{"key":"720_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00005344-199608000-00022","volume":"28","author":"H Vidrio","year":"1996","unstructured":"Vidrio H, S\u00e1nchez-Salvatori MA, Medina M (1996) Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28:332\u2013336. https:\/\/doi.org\/10.1097\/00005344-199608000-00022","journal-title":"J Cardiovasc Pharmacol"},{"key":"720_CR43","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1113\/jphysiol.2004.064824","volume":"558","author":"P Pacher","year":"2004","unstructured":"Pacher P, B\u00e1tkai S, Kunos G (2004) Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 558:647\u2013657. https:\/\/doi.org\/10.1113\/jphysiol.2004.064824","journal-title":"J Physiol"},{"key":"720_CR44","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1111\/bph.12734","volume":"171","author":"LT Al Kury","year":"2014","unstructured":"Al Kury LT, Voitychuk OI, Yang KH, Thayyullathil FT, Doroshenko P, Ramez AM, Shuba YM, Galadari S, Howarth FC, Oz M (2014) Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. Br J Pharmacol 171:3485\u20133498. https:\/\/doi.org\/10.1111\/bph.12734","journal-title":"Br J Pharmacol"},{"key":"720_CR45","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/j.1476-5381.2009.00518.x","volume":"158","author":"Q Li","year":"2009","unstructured":"Li Q, Ma HJ, Zhang H, Qi Z, Guan Y, Zhang Y (2009) Electrophysiological effects of anandamide on rat myocardium. Br J Pharmacol 158:2022\u20132029. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00518.x","journal-title":"Br J Pharmacol"},{"key":"720_CR46","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1039\/c6tx00259e","volume":"5","author":"J Yun","year":"2016","unstructured":"Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo H, Shin J, Park HK, Kim HS, Kim YH (2016) Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res (Camb) 5:1663\u20131671. https:\/\/doi.org\/10.1039\/c6tx00259e","journal-title":"Toxicol Res (Camb)"},{"key":"720_CR47","doi-asserted-by":"publisher","first-page":"204209862091341","DOI":"10.1177\/2042098620913416","volume":"11","author":"JC Hancox","year":"2020","unstructured":"Hancox JC, Kalk NJ, Henderson G (2020) Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users. Ther Adv Drug Saf 11:2042098620913416. https:\/\/doi.org\/10.1177\/2042098620913416","journal-title":"Ther Adv Drug Saf"},{"key":"720_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13181-014-0424-1","volume":"11","author":"RG McKeever","year":"2015","unstructured":"McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI (2015) K2\u2013not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol 11:129\u2013131. https:\/\/doi.org\/10.1007\/s13181-014-0424-1","journal-title":"J Med Toxicol"},{"key":"720_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5863\/1551-6776-17.2.177","volume":"17","author":"TS Heath","year":"2012","unstructured":"Heath TS, Burroughs Z, Thompson AJ, Tecklenburg FW (2012) Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther 17:177\u2013181. https:\/\/doi.org\/10.5863\/1551-6776-17.2.177","journal-title":"J Pediatr Pharmacol Ther"},{"key":"720_CR50","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/1556-4029.13704","volume":"63","author":"ABM Paul","year":"2018","unstructured":"Paul ABM, Simms L, Amini S, Paul AE (2018) Teens and spice: a review of adolescent fatalities associated with synthetic cannabinoid use. J Forensic Sci 63:1321\u20131324. https:\/\/doi.org\/10.1111\/1556-4029.13704","journal-title":"J Forensic Sci"},{"issue":"2005","key":"720_CR51","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nn1457","volume":"8","author":"V Di Marzo","year":"2005","unstructured":"Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8(2005):585\u2013589. https:\/\/doi.org\/10.1038\/nn1457","journal-title":"Nat Neurosci"},{"key":"720_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1527-3458.2006.00091.x","volume":"12","author":"MA Carai","year":"2006","unstructured":"Carai MA, Colombo G, Maccioni P, Gessa GL (2006) Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 12:91\u201399. https:\/\/doi.org\/10.1111\/j.1527-3458.2006.00091.x","journal-title":"CNS Drug Rev"},{"key":"720_CR53","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s11064-009-9914-y","volume":"34","author":"VS Dalton","year":"2009","unstructured":"Dalton VS, Wang H, Zavitsanou K (2009) HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 34:1343\u20131353. https:\/\/doi.org\/10.1007\/s11064-009-9914-y","journal-title":"Neurochem Res"},{"key":"720_CR54","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2131\/jts.39.815","volume":"39","author":"T Ashino","year":"2014","unstructured":"Ashino T, Hakukawa K, Itoh Y, Numazawa S (2014) Inhibitory effect of synthetic cannabinoids on CYP1A activity in mouse liver microsomes. J Toxicol Sci 39:815\u2013820. https:\/\/doi.org\/10.2131\/jts.39.815","journal-title":"J Toxicol Sci"},{"key":"720_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/187231280701131211151523","volume":"7","author":"KC Chimalakonda","year":"2013","unstructured":"Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH (2013) Sulfaphenazole and \u03b1-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2\/spice. Drug Metab Lett 7:34\u201338. https:\/\/doi.org\/10.2174\/187231280701131211151523","journal-title":"Drug Metab Lett"},{"key":"720_CR56","doi-asserted-by":"publisher","first-page":"21917","DOI":"10.1371\/journal.pone.0021917","volume":"6","author":"LK Brents","year":"2011","unstructured":"Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 6:21917. https:\/\/doi.org\/10.1371\/journal.pone.0021917","journal-title":"PLoS ONE"},{"key":"720_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.taap.2013.03.012","volume":"269","author":"M Rajasekaran","year":"2013","unstructured":"Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL (2013) Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269:100\u2013108. https:\/\/doi.org\/10.1016\/j.taap.2013.03.012","journal-title":"Toxicol Appl Pharmacol"},{"key":"720_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.forsciint.2010.01.004","volume":"198","author":"N Uchiyama","year":"2010","unstructured":"Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31\u201338. https:\/\/doi.org\/10.1016\/j.forsciint.2010.01.004","journal-title":"Forensic Sci Int"},{"key":"720_CR59","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00216-010-4171-0","volume":"398","author":"A Wintermeyer","year":"2010","unstructured":"Wintermeyer A, M\u00f6ller I, Thevis M, J\u00fcbner M, Beike J, Rothschild MA, Bender K (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141\u20132153. https:\/\/doi.org\/10.1007\/s00216-010-4171-0","journal-title":"Anal Bioanal Chem"},{"key":"720_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/jcph.827","volume":"57","author":"CM White","year":"2017","unstructured":"White CM (2017) The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol 57:297\u2013304. https:\/\/doi.org\/10.1002\/jcph.827","journal-title":"J Clin Pharmacol"},{"key":"720_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12\u201341. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.08.005","journal-title":"Drug Alcohol Depend"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-025-00720-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-025-00720-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-025-00720-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:51:26Z","timestamp":1752137486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-025-00720-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s11419-025-00720-9","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An application was made to Inonu University Faculty of Medicine Animal Experiments Local Ethics Committee for ethical approval, and ethics committee permission was obtained at the meeting dated 26.08.2015 with ethical approval number 2015\/A-24.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}